Corona Giovanni, Petrone Luisa, Fisher Alessandra D, Mansani Riccardo, Bandini Elisa, Boddi Valentina, Lotti Francesco, Forti Gianni, Maggi Mario
Andrology Unit, Department of Clinical Physiopathology, University of Florence, Florence, Italy.
Arch Ital Urol Androl. 2008 Sep;80(3):103-8.
The relationship between hypogonadism and erectile dysfunction (ED) has not been completely clarified. Data derived from studies evaluating the effect of testosterone (T) replacement therapy (TRT) on patients with ED have yield mixed results. The purpose of the present study was to evaluate the efficacy and safety of a 50 mg/day of 1% hydroalcoholic testosterone gel applied on non-scrotal skin for hypogonadal men with sexual dysfunction.
We studied a consecutive series of 85 hypogonadal (total testosterone < 12 nmol/L) men (mean age 51.0 +/- 14.0 years) attending our Andrological Unit. Patients were interviewed using ANDROTEST structured interview, a 12-item tool previously validated for the screening of hypogonadism in patients with sexual dysfunction. Patients were also invited to complete erectile function domain of International Index of Erectile Function (IIEF-6;11). Different clinical and biochemical parameters were evaluated at baseline and after 6 months of TRT.
Subjects with ED at baseline (61.2%) showed significant increase of IIEF-6 score after 6 months of TRT (9.7 +/- 7.7 vs. 14.6 +/- 9.8, p < 0.001). Furthermore, subjects with more severe hypogonadism at baseline (T in the lowest quartile) showed the best increase in IIEF-6 score. All haematological and biochemical parameters tested remained in the normal rage at the end of the study.
Our study demonstrated that 1% hydroalcoholic testosterone gel is an effective and safe treatment option in subjects with ED.
性腺功能减退与勃起功能障碍(ED)之间的关系尚未完全阐明。评估睾酮(T)替代疗法(TRT)对ED患者疗效的研究所得出的数据结果不一。本研究的目的是评估每天50毫克1%水醇性睾酮凝胶涂抹于非阴囊皮肤对性腺功能减退伴性功能障碍男性的疗效和安全性。
我们研究了连续纳入男科门诊的85例性腺功能减退(总睾酮<12 nmol/L)男性(平均年龄51.0±14.0岁)。采用ANDROTEST结构化访谈对患者进行询问,这是一种先前经验证可用于筛查性功能障碍患者性腺功能减退的12项工具。还邀请患者完成国际勃起功能指数(IIEF-6;11)中的勃起功能领域评估。在基线和TRT治疗6个月后评估不同的临床和生化参数。
基线时患有ED的受试者(61.2%)在TRT治疗6个月后IIEF-6评分显著增加(9.7±7.7对14.6±9.8,p<0.001)。此外,基线时性腺功能减退更严重(T处于最低四分位数)的受试者IIEF-6评分增加最多。研究结束时,所有检测的血液学和生化参数均保持在正常范围内。
我们的研究表明,1%水醇性睾酮凝胶对患有ED的受试者是一种有效且安全的治疗选择。